HPV vaccination in women over 25 years of age: Asian cervical cancer prevention advisory board recommendations

Journal of Obstetrics and Gynaecology Research

Volumn 35, Issue 4, 2009, Pages 712-716

  Basu, Partha ^a   Ngan, Hextan Yuen Sheung ^b   Hseon, Tay Eng ^c  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Cervix cancer; Human papillomavirus; Vaccine; Women over 25 years

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; INFECTION PREVENTION; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREVALENCE; SEROCONVERSION; SEXUAL BEHAVIOR; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VIRUS INFECTION;

ADULT; AGE FACTORS; ASIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS;

EID: 70049097927     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01022.x     Document Type: Article

References (18)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base No. 5, version 2.0. Lyon : IARC Press, 2004.
2. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent l1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004 364 : 1757 1765.
3. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003 31 : 3 13.
4. Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 111 : 278 285.
5. Schwarz TF. Human papillomavirus - 16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev. Obstet Gynecol 2007 2 : 293 303.
6. Muñoz N, Bosch FX, de Sanjose S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 527.
7. Grainge MJ, Seth R, Guo L et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005 11 : 1680 1685.
8. Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005 191 : 1808 1816.
9. García-Piñeres AJ, Hildesheim A, Herrero R et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006 66 : 11070 11076.
10. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006 24 (Suppl 3 S106 S113.
11. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005 97 : 1072 1079.
12. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic disease. Vaccine 2006 24 (Suppl 3 S26 S34.
13. Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 189 : 1 3.
14. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006 367 : 1247 1255.
15. Paavonen J, Jenkins D, Bosch FX et al. HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007 369 : 2161 2170.
16. Hildesheim A, Herrero R, Wacholder S et al. Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007 298 : 743 753.
17. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 95 : 1459 1466.
18. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001 79 : 954 962.